Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,824 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07625280RecruitingPhase 3
Twice-nightly treatment for narcolepsy or idiopathic hypersomnia
This study tests whether taking the sleep medicine Xywav two times each night is safe and helps control symptoms better than a placebo. People with narcolepsy or idiopathic hypersomnia may join, including those who have not tried oxybate medicines before.
Los Angeles, CaliforniaAges 18–75 - NCT07481981RecruitingPhase 3
Study of once-daily inhaled TPIP for pulmonary arterial hypertension
This trial tests an inhaled medication (TPIP) that opens blood vessels in the lungs to help you breathe easier and be more active. It is for people with PAH who are already on stable treatment and have moderate symptoms.
Santa Barbara, CaliforniaAges 18–75 - NCT06937229RecruitingPhase 3
Long-term study of KarXT for agitation in Alzheimer's
This trial tests if KarXT, taken with KarX-EC, is safe and effective for long-term treatment of agitation in Alzheimer's disease. It is for people who already completed a previous KarXT study.
Chandler, ArizonaAges 55–90 - NCT07447986RecruitingPhase 2
Testing a New Injection for Lupus (SLE)
This study tests a new injectable medicine (SG301) for people with lupus (SLE) whose current treatments are not working well enough or cause side effects. It aims to see if this targeted therapy can better control lupus symptoms.
Beijing, Beijing MunicipalityAges 18–70 - NCT05776927RecruitingPhase 3
Testing a new inhaler for teens with asthma
This trial tests a new combination inhaler (QVM149) against a standard one (Advair) in teenagers with asthma that isn't well controlled by their current medicine. It aims to see if the new inhaler works better.
Germiston, GautengAges 12–17 - NCT07365319RecruitingPhase 2/Phase 3
New drug combo for stage 4 lung cancer
This trial tests a new drug called EIK1001 combined with standard immunotherapy (pembrolizumab) and chemotherapy for people with stage 4 non-small cell lung cancer who have not been treated before. The goal is to see if adding EIK1001 helps shrink tumors more than the current standard treatment.
Daphne, AlabamaAges 18 years+ - NCT06865651RecruitingPhase 2
Study of Remibrutinib for chronic hives not helped by antihistamines
This trial tests an experimental drug called Remibrutinib for people with chronic hives (urticaria) that are not well controlled with standard antihistamines. The goal is to see if the drug reduces symptoms like itching and wheals.
North Miami Beach, FloridaAges 18 years+ - NCT07565285RecruitingPhase 2
Combination Treatment for Operable Stage III Skin Melanoma
This study tests whether combining a new drug called PRTX007-003 with pembrolizumab (an immunotherapy) can help prevent melanoma from returning after surgery. You would receive both treatments after your tumor is surgically removed.
Waratah, New South WalesAges 18 years+ - NCT05977673RecruitingPhase 2
Tislelizumab for untreated Hodgkin lymphoma when chemo isn’t suitable
This Phase 2 trial tests tislelizumab (an immune therapy) in people with newly diagnosed classical Hodgkin lymphoma who cannot safely get standard chemotherapy. It aims to see how well the treatment works and whether it is safe for older adults and others with health limits.
Alessandria, ITAges 65 years+ - NCT06439082RecruitingPhase 3
Crizanlizumab for sickle cell pain crises
This trial tests whether crizanlizumab can reduce painful sickle cell crises (called vaso-occlusive crises or VOCs) in people with sickle cell disease who have frequent crises. It may be an option for those who still have crises despite current treatments.
Birmingham, AlabamaAges 12–100 - NCT07221851RecruitingPhase 3
Weekly vs daily growth hormone for short stature in children
This trial tests a weekly growth hormone injection (lonapegsomatropin) compared to the standard daily growth hormone shot in children with short stature due to certain conditions. It aims to see if the weekly shot works as well or better and is safe.
Palo Alto, CaliforniaAges 2–17 - NCT07378644RecruitingPhase 2/Phase 3
Testing SKY-0515 for Huntington's disease
This trial tests a new drug called SKY-0515 in people with Huntington's disease. The goal is to see if it can safely improve symptoms or slow the disease down.
Englewood, ColoradoAges 25 years+ - NCT07431177RecruitingPhase 2
Study of an investigational drug for non-segmental vitiligo
This study tests an investigational drug (GIA632) in people with non-segmental vitiligo. It aims to see if different doses can safely and effectively restore color to white patches.
Birmingham, AlabamaAges 18–99 - NCT05562466RecruitingPhase 3
Tested inhaler for children with asthma ages 6–11
This Phase 3 study compares a new inhaler (QMF149: indacaterol plus mometasone) against budesonide to see which works better and is safe for children ages 6 to under 12 with asthma. You may be able to join if your child is already on a stable low-dose steroid inhaler and still has symptoms.
CABA, Buenos AiresAges 6–11 - NCT06947993RecruitingPhase 2
Study of a new treatment for moderate to severe eczema
This study tests an experimental treatment for people with moderate to severe eczema that has lasted at least a year. It aims to see if the new medicine can help control symptoms better than current options.
Birmingham, AlabamaAges 18–100 - NCT07726888Recruiting
Guselkumab for moderate-to-severe ulcerative colitis
This study tests a drug called Guselkumab (already approved for other conditions) for treating moderate to severe ulcerative colitis. It aims to see how safe and effective the drug is in real-world patients who have not had success with other treatments.
Wenzhou, ZhejiangAges 18 years+ - NCT07769528Recruiting
Heart pump support for severe heart failure
This study tests a device that helps the heart pump blood when it is too weak to do so, even with medicine, after surgery, or while waiting for a transplant. It aims to see if it's safe and works well.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07489651RecruitingPhase 2
New treatment for generalized anxiety disorder
This trial tests a new medication called RE104 for people with generalized anxiety disorder (GAD). The goal is to see if it helps reduce anxiety symptoms safely.
Birmingham, AlabamaAges 18–74 - NCT07094087RecruitingPhase 3
Blood clotting medicine for heart surgery bleeding
This trial tests a medicine called 4F-PCC to stop bleeding during complex heart surgery that uses a heart-lung machine. It could help people who have bleeding problems after the surgery.
Los Angeles, CaliforniaAges 18 years+ - NCT07665437RecruitingPhase 3
Long-term safety study of remibrutinib for hidradenitis suppurativa
This study tests the long-term safety and effectiveness of remibrutinib for people with moderate to severe hidradenitis suppurativa (HS) who have already completed a 68-week treatment period in a related study.
Fort Smith, ArkansasAges 18–100 - NCT03059043Recruiting
ICL lens surgery using a low-contact method in near-sighted eyes
This trial studies whether a specific, “viscoelastic-free” technique for implantable collamer lens (ICL) surgery is safe and works well for people with stable near-sightedness. It may help by improving the way the lens is inserted while closely monitoring eye safety and vision results.
Guangzhou, GuangdongAges 18–45 - NCT07621809RecruitingPhase 3
Ianalumab versus placebo for Sjögren's disease with high symptom burden
This study tests whether a new drug called ianalumab can reduce dry mouth and other symptoms in people with Sjögren's disease—a condition where the immune system attacks moisture-producing glands. Participants will receive either ianalumab or a placebo (inactive injection) over 52 weeks to see if the drug helps.
Peoria, ArizonaAges 18 years+ - NCT07214376Recruiting
Nerve ablation for pulmonary hypertension from left heart disease
This trial tests a device that uses a catheter to deliver energy to nerves around the pulmonary arteries, aiming to reduce high blood pressure in the lungs caused by left heart failure. It is for people with ongoing heart failure symptoms despite optimal medications.
Tucson, ArizonaAges 18–85 - NCT06826079RecruitingPhase 2
Sorbitol plus chemo and immunotherapy for advanced gastric cancer
This trial tests adding sorbitol to standard chemotherapy and an immunotherapy drug (tirellizumab) for people with locally advanced stomach cancer. The goal is to see if this combination is safe and helps shrink tumors before surgery.
Wuhan, HubeiAges 18–70
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,824 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.